Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn
2024年8月1日 - 1:30AM
ビジネスワイヤ(英語)
The Parker Institute for Cancer Immunotherapy (PICI) today
announced the appointments of Ansu Satpathy, MD, PhD, Julia
Carnevale, MD, and Saar Gill, MBBS, PhD, FRACP, as Co-Directors of
the PICI Centers at Stanford Medicine, University of California,
San Francisco, and the University of Pennsylvania, respectively.
These appointments reflect PICI's strategy to leverage leaders with
expertise in translating scientific discoveries into innovative
cancer immunotherapies, accelerating the development of
breakthrough treatments through collaboration.
The new Co-Directors are distinguished leaders in cancer
immunotherapy research. Dr. Satpathy, a longstanding PICI
Investigator and former Parker Bridge Scholar, has made significant
advances in T cell immunotherapies and genomics. Dr. Carnevale has
pioneered innovative approaches in T cell engineering and
large-scale CRISPR screening. Dr. Gill is known for his numerous
contributions to cellular therapy and genetic engineering for blood
cancers.
Importantly, these leaders bring extensive expertise at
translating scientific discoveries into new technologies and
treatments, as well as building the companies that will deliver
them to patients. Dr. Satpathy has co-founded biotech companies
including Cartography Biosciences and Immunai, which are applying
advanced genomics to enhance immunotherapy development. Dr. Gill
has launched Carisma Therapeutics and Interius Biotherapeutics,
moving novel cell therapies from lab to clinic. Dr. Carnevale’s
patented CRISPR screening method is propelling the creation of
next-generation cell therapies, laying the groundwork for future
biotech ventures.
"In Drs. Satpathy, Carnevale and Gill, we have leaders who
bridge the gap between scientific discovery and advancing new
treatments to patients," said PICI Chief Scientific Officer John
Connolly, PhD. "Each is a leading expert in their field, with a
shared passion for advancing cancer immunotherapy and a commitment
to collaborating across institutions to accelerate the development
of breakthrough immune therapies."
At Stanford Medicine, Dr. Satpathy joins Crystal Mackall, MD,
Director of the PICI Center at Stanford Medicine, and Co-Director
Mark Davis, PhD, in site leadership.
"Ansu brings a rare combination of scientific insight and
translational expertise to his new role as Co-Director of our PICI
Center," said Dr. Mackall. "His groundbreaking work in
immunogenomics, coupled with his success in launching multiple
biotechnology ventures, demonstrates his ability to transform
complex biological concepts into viable clinical strategies. This
blend of scientific rigor and practical application is essential
for accelerating our progress in cancer immunotherapy."
Dr. Carnevale joins the leadership of the PICI Center at UCSF,
partnering with Center Director Kole Roybal, PhD. She succeeds
Lawrence Fong, MD, who has joined the Fred Hutchinson Cancer Center
in Seattle as Scientific Director of the Immunotherapy Integrated
Research Center (IIRC). PICI thanks Dr. Fong for his leadership and
contributions to the PICI Center at UCSF.
"Julia's pioneering work in CRISPR-based T cell engineering
brings a unique and powerful skillset to our team," said Dr.
Roybal. "As a physician-scientist, she's the ideal clinical
counterpart to our research efforts, bridging bench discoveries
with therapeutic applications. Her leadership will be key in
translating our advanced engineered immune cell therapies from the
lab to patients."
Rounding out the trio of appointments, at Penn, Dr. Gill joins
Carl June, MD, Director of the PICI Center at the University of
Pennsylvania and E. John Wherry, PhD, Center Co-Director.
"Saar's exceptional expertise in translational research,
combined with his novel insights from regenerative medicine, will
undoubtedly propel our immunotherapy efforts at the PICI Center. I
look forward to our continued scientific partnership in advancing
transformative cancer treatment modalities," said Dr. June.
Learn more about the new Co-Directors by visiting the PICI
website.
About the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is
radically changing how cancer research is done. Founded in 2016
through a $250 million gift from Silicon Valley entrepreneur and
philanthropist Sean Parker, with an additional $125 million
commitment announced in 2024, the San Francisco-based nonprofit is
an unprecedented collaboration between the country’s leading
immunotherapy researchers and cancer centers. PICI Network research
institutions include Stanford Medicine; the University of
California, Los Angeles; the University of California, San
Francisco; the University of Pennsylvania; Dana-Farber Cancer
Institute; Gladstone Institutes; and Weill Cornell Medicine. PICI
also supports top researchers at other institutions, including The
University of Texas MD Anderson Cancer Center, Memorial Sloan
Kettering Cancer Center, City of Hope, Fred Hutchinson Cancer
Research Center, Icahn School of Medicine at Mount Sinai, Institute
for Systems Biology and Washington University School of Medicine in
St. Louis. By forging alliances with academic, industry and
nonprofit partners, PICI makes big bets on bold research to fulfill
its mission: to accelerate the development of breakthrough
immunotherapies to turn all cancers into curable diseases. Find out
more at parkerici.org and follow us on LinkedIn, X, Apple Podcasts
and Spotify.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731312204/en/
Parker Institute for Cancer Immunotherapy (PICI) Eric McKeeby
emckeeby@parkerici.org
1AB Dan Budwick dan@1abmedia.com